Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545558 · ClinicalTrials.gov registry record · Phase 1
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
A Phase 1 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00545558 is a Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 18 participants.
The verdict
NCT00545558, a Phase 1 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.
Interventions
- DRUG Efavirenz
- DRUG Emtricitabine/Tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00545558
The ClinicalTrials.gov registry entry for NCT00545558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT00545558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00545558 about?
NCT00545558 is a clinical study titled "Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV". The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.
What is the current status of trial NCT00545558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-04. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00545558?
The interventions under investigation include: Efavirenz (DRUG), Emtricitabine/Tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00545558?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.